GHK-Cu
The copper componentA three-part peptide bound to copper. The skincare ingredient name Copper Tripeptide-1 belongs to the topical context: products placed on skin.
Blend study / 02
Glow peptide: a name, not a result.
This guide explains the Glow blend and the extra questions that come with a mixture. Glow names a combination of GHK-Cu, BPC-157 and TB-500. It does not establish a skin result or make the blend an approved medicine.
Licensed U.S. provider review
Start a Promise Peptides Glow visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider reviews every request and decides whether a prescription is appropriate. Not everyone qualifies. Compounded medicines are made to order. They are not approved by the U.S. Food and Drug Administration (FDA).
U.S. patients only. Availability varies by state and by treatment.
Three parts to the name
What is in the Glow blend?
A peptide is a short chain of amino acids, the building blocks of proteins. A blend brings several peptides together.
BPC-157
A lab-made peptideA peptide based on part of a protein reported in stomach fluid. It is made in a lab and has no drug approval from the U.S. Food and Drug Administration (FDA).
TB-500
A small peptide fragmentA lab-made fragment, or small piece, of thymosin beta-4. TB-500 is different from that full-length peptide. Their research cannot be treated as interchangeable.
Beyond the ingredient list
A mixture needs its own evidence
Glow is not an FDA-approved drug. It is a blend name rather than one standard, approved formula. The name alone does not specify a product's form or establish its quality.
Evidence about a single ingredient does not show what happens when ingredients are put together. The same caution applies to safety. An ingredient list cannot answer every question about a combination.
GHK-Cu has lab, animal and small topical human studies. FDA found no published patient treatment study of TB-500 in its review. Studies of full-length thymosin beta-4 do not fill that gap.
This is why a description such as “skin peptide” is only a starting point. A provider has to consider the particular preparation and the evidence behind it, rather than treating a blend name as a finding from a study in people.
What the rules still ask
On FDA's page current as of April 22, 2026, BPC-157, TB-500 and injectable GHK-Cu appear as “nominated but withdrawn.” This means the requests for their review were taken back. FDA still publishes safety concerns beside those entries.
Withdrawal is not clearance and is not approval for compounding. FDA publishes no per-substance withdrawal dates on that page. A prescription discussion cannot change the ingredient rules.
Compounding means preparing a medicine to order. Compounded medicines are not FDA-approved. A licensed provider's decision and a pharmacy's legal decision are both separate from FDA approval.
Questions about the whole blend
The useful questions concern the mixture, not just its best-known ingredient.
- What is the exact preparation and intended form?
- Is the human evidence about this mixture, or only a separate ingredient?
- What is known about the combination's safety?
- Can a pharmacy lawfully prepare this particular prescription?
Where KLOW differs
KLOW combines GHK-Cu, BPC-157 and TB-500 with KPV, a small peptide made of lysine, proline and valine. That is another ingredient to assess. It does not establish that one blend is better than the other.
Compare GHK-Cu, Glow and KLOWSources for this page
- FDA's peptide safety concerns and withdrawn requestsU.S. Food and Drug Administration
- FDA's questions and answers about compoundingU.S. Food and Drug Administration
- FDA's review of TB-500U.S. Food and Drug Administration · July 2026 briefing
The next page is yours
Keep the licensed route in view
A visit begins a review. A licensed U.S. provider decides whether a prescription is appropriate. Not everyone qualifies, and availability varies by state and by treatment.
Licensed U.S. provider review
Start a Promise Glow visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider is a health professional who can make prescription decisions. One reviews every request and decides whether to prescribe. Not everyone qualifies.
Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved. A pharmacy separately decides whether it can lawfully prepare a prescription.
U.S. patients only. Availability varies by state and by treatment.
Promise is LegitScript-certified. That certification is not FDA approval.